Charlotte's Web Holdings, Inc. (CWBHF) Stock Price & Analysis
Charlotte's Web Holdings, Inc. (CWBHF) closed at USD 0.28 on Friday, October 23, 2026, up 12.65% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.25; the Oct 23, 2026 session ranged USD 0.26–0.28 on volume of 9,010 shares. Market capitalization is $74.88M, with a 52-week range of USD 0.08–0.97 (OQX). Source: Nexqual, retrieved October 24, 2026 at 14:10 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CWBHF.md
Key facts (CWBHF)
- Last four reported quarters (through Jun 30, 2026): revenue $46.8M, net income -$34.5M (-73.6% margin), free cash flow -$11.1M (SEC filings).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $39K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts).
- Total return with dividends: 1Y +64.3% vs S&P 500 +13.4%; 5Y -83.2% vs S&P 500 +76.9%.
- Next earnings: 2026-11-11, EPS estimate USD -0.02, revenue estimate $9.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CWBHF)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $96.1M | $74.1M | $63.2M | $49.7M | $49.9M | $46.8M |
| Gross profit | $48.6M | $19.4M | $35.6M | $21.3M | $21.7M | — |
| Operating income | -$147M | -$52.5M | -$40.6M | -$32.0M | -$20.3M | -$19.5M |
| Net income | -$138M | -$59.3M | -$23.8M | -$29.8M | -$29.7M | -$34.5M |
| EPS (diluted) | -$0.98 | -$0.40 | -$0.16 | -$0.19 | -$0.19 | — |
| Free cash flow | -$34.5M | -$5.6M | -$19.1M | -$25.1M | -$14.7M | -$11.1M |
| Gross margin | 50.6% | 26.2% | 56.3% | 42.8% | 43.5% | — |
| Operating margin | -153.0% | -70.8% | -64.3% | -64.4% | -40.6% | -41.7% |
| Net margin | -143.3% | -80.0% | -37.7% | -60.1% | -59.6% | -73.6% |
| Revenue growth | +0.9% | -22.8% | -14.8% | -21.4% | +0.5% | — |
| Cash + short-term investments | $19.5M | $67.0M | $47.8M | $22.6M | $8.0M | — |
| Total debt | $0K | $37.4M | $42.5M | $43.6M | $50.8M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CWBHF)
P/S 1.6x · EV/Sales 1.3x · P/B 1.3x · FCF yield -14.82% · Earnings yield -46.05% · Net cash $14.0M · EV $60.9M
Insider purchases (SEC Form 4, open-market, last ~7 months) (CWBHF)
1 purchase, $39K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-03 | Kunkel Raymond J. | Chief Operating Officer | 137,935 | $39K | 0.28 | Too little history (no open-market trades in 2023) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CWBHF)
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts.
Total return (dividends reinvested) (CWBHF)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +64.3% | -83.2% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +64.6% | -30.0% |
| Volatility (annualized) | 129.6% | 100.1% |
| Max drawdown | -76.6% (Feb 2026→Jul 2026) | -96.1% (Nov 2021→Mar 2025) |
CWBHF revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product revenue | $10.8M | 99.3% | -15.3% |
| Service revenue | $75,000 | 0.7% | +0.0% |
| Total revenue | $10.9M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CWBHF company outlook (results filed Aug 13, 2026)
- “Alongside the ASD program, DeFloria is evaluating multiple rare pediatric neurological indications for AJA001, each of which would be expected to be eligible for orphan drug designation.”
- “Operationally, gross margin improved to 47.5% from 46.8% despite lower volume, and we expect the second half to show further cost improvement.”
- “Management expects gross margin to continue improving toward the Company's target range of approximately 50%, supported by the shift away from lower-margin sales channels, reduced discounting, and cost benefits as in-house manufacturing scales.”
- “The Company continues to expect quarterly SG&A to remain in a normalized range of approximately $10 million.”
Quoted word-for-word from the SEC 8-K results press release.
CWBHF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.02 | $-0.02 | +0.0% | $9.2M | 1 |
| Next quarter (ends Dec 2026) | $-0.02 | $-0.02 | +0.0% | $9.4M | 1 |
| Current fiscal year (ends Dec 2026) | $-0.14 | $-0.15 | -6.7% | $40.6M | 1 |
| Next fiscal year (ends Dec 2027) | $-0.05 | $0.01 | -600.0% | $43.5M | 1 |
Key Statistics (as of October 24, 2026 at 14:10 UTC)
| Price | USD 0.28 |
|---|---|
| Change | ▲ 12.65% (up) |
| Previous Close | USD 0.25 |
| Open | USD 0.26 |
| Day Range | USD 0.26 – 0.28 |
| 52-Week Range | USD 0.08 – 0.97 |
| Volume | 9,010 shares |
| Market Cap | $74.88M |
| Exchange | OQX |
Technical Analysis (CWBHF)
Nexqual's technical model rates CWBHF "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 24, 2026 at 14:10 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.1 (neutral) |
| vs SMA50 | Below (USD 0.3) |
| MACD | -0.01 (negative) |
Analyst Ratings (CWBHF)
Wall Street analysts rate CWBHF "Buy" based on 1 analysts, per Nexqual as of October 24, 2026 at 14:10 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CWBHF)
| Next Earnings Date | 2026-11-11 |
|---|---|
| Revenue Estimate | $9.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.02 vs est -0.02 ▲ beat |
| 2026-03-31 | USD -0.08 vs est -0.1 ▲ beat |
Source: Nexqual, October 24, 2026 at 14:10 UTC.
Financials & Fundamentals (CWBHF)
| Total Revenue | $46.84M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -15.20% |
| Gross Margin | +42.36% |
| Operating Margin | -40.15% |
| Profit Margin | -73.61% |
| ROE | -97.14% |
| Debt / Equity | 0.23 |
| Current Ratio | 4.19 |
| Total Cash | $13.99M |
| Total Debt | $13.05M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$11.09M (-23.7% of revenue) |
Source: Nexqual, October 24, 2026 at 14:10 UTC.
Financial Health Score (CWBHF)
Nexqual rates Charlotte's Web Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 14:10 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $14M cash and investments, no debt (Jun 2026, SEC) |
| Cash Flow | Weak — FCF negative: -$11M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -97%, ROA -14.9% |
Ownership (CWBHF)
| Insider Ownership | +47.34% |
|---|---|
| Institutional Ownership | +1.36% |
| Shares Outstanding | 271.29M |
| Float | 153.98M |
Source: Nexqual, October 24, 2026 at 14:10 UTC.
From Charlotte's Web Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- The Company is a substantially vertically integrated company that performs its own manufacturing for proprietary elements in the manufacturing process.
- Through its substantially vertically integrated business model, the Company strives to improve customers' lives and meet their demands for stringent product quality and consistency.
Partnerships
- In October 2022, the Company entered into a Promotional Rights Agreement (the "MLB Promotional Rights Agreement") with MLB Advanced Media L.P., on its own behalf and on behalf of Major League Baseball Properties, Inc., the Office of the Commissioner of Baseball, The MLB Network, LLC and the Major League Baseball Clubs (collectively, the "MLB"), pursuant to which the Company entered into an exclusive strategic partnership with MLB.
- On October 11, 2022, the Company entered into a Promotional Rights Agreement (the "MLB Promotional Rights Agreement") with MLB Advanced Media L.P., on its own behalf and on behalf of Major League Baseball Properties, Inc., the Office of the Commissioner of Baseball, The MLB Network, LLC and the Major League Baseball Clubs (collectively, the "MLB"), pursuant to which the Company entered into an exclusive strategic partnership with MLB.
Legal & Regulatory Risks (Item 1A, quoted)
- The Company's products are subject to numerous and diverse regulatory requirements which may restrict the Company's ability to sell its product, and regulatory compliance costs may affect the Company's business and financial results.
- Failure to comply with FDA requirements may result in, among other things, injunctions, product withdrawals, recalls, product seizures, fines and criminal prosecutions.
- Failure by the Company to comply with the current or evolving regulatory framework at the federal, state, and local level could have a material adverse impact on the Company's business, financial condition and results of operations.
- The Company is subject to regulations that could impact its ability to sell its product internationally.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 40.7 | ▼ 3.26% |
| BHC | Bausch Health Companies Inc. | USD 6.44 | ▼ 0.77% |
| HCM | HUTCHMED (China) Limited | USD 14.36 | ▲ 0.56% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.2 | ▼ 4.8% |
| RGC | Regencell Bioscience Holdings L | USD 7.67 | ▼ 21.81% |
| LQDA | Liquidia Corporation | USD 42.65 | ▲ 7.46% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 14:10 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt